| WellPoint Withdraws Rate Proposal WellPoint said it would revise its request for steep rate hikes in California's individual market, after a state regulator said it found flaws in the company's application. online.wsj.com |
MannKind Bear Analysts Strike Again KLLJ Investments submits: The nice thing about being a bad Wall Street analyst, is nobody knows how bad you are until your call goes terribly wrong. Often times, there are more forces at work to bring about a poor recommendation. I’m not saying that is necessarily the case here, but you have to wonder. My local weatherman is usually more accurate about my 10-day forecast than a majority of the Wall Street analysts out there. What is unfortunate is how much an upgrade or downgrade can impact the short term trend of a security, especially when those recommendations are based on little, if any research. Many investors look to the Analysts as being experts in the firms they cover and those analysts who fail to live up to their duty as an independent auditor of sorts for those companies do a disservice to their profession.Complete Story » seekingalpha.com |
FDA Panel Rejects Weight-Loss Drug A federal advisory panel narrowly rejected Vivus's experimental weight-loss drug Qnexa on potential safety concerns. online.wsj.com |
Study Examines Sugar as Pain Reliever for Tots In The Research Report, Jeremy Singer-Vine summarizes new medical findings on infant pain; circadian rhythms; lung cancer; cognitive exercise; migraine; low-carbohydrate diets; esophageal cancer and heart health. online.wsj.com |
FDA Issues Rule on Drug Trials The FDA clarified what safety information must be reported during clinical trials of investigational drugs and biologics, bringing it in line with standards from other organizations. online.wsj.com |